Q THERAPEUTICS, INC. Financial Statements (2026 and earlier)

Company Profile

Business Address 615 ARAPEEN DRIVE
SALT LAKE CITY, UT 84108
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

9/30/2015
MRQ
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 707143794
Cash and cash equivalent 707143794
Receivables 4 449
Deferred costs  63 
Prepaid expense and other current assets✕✕✕10
Other undisclosed current assets 111629
Total current assets: 7222221,282
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization 272816
Long-term investments and receivables   29
Due from related parties   29
Other undisclosed noncurrent assets  8(21)
Total noncurrent assets: 273624
TOTAL ASSETS: 7482571,306
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 1,0122,7991,301
Employee-related liabilities 70635488
Accounts payable 2642,3641,203
Accrued liabilities 438110
Debt  500 
Derivative instruments and hedges, liabilities 32  
Total current liabilities: 1,0443,2991,301
Noncurrent Liabilities
Total liabilities: 1,0443,2991,301
Equity
Equity, attributable to parent, including: (296)(3,042)5
Common stock 322
Additional paid in capital 26,93320,83720,495
Accumulated deficit (27,232) (20,492)
Other undisclosed equity, attributable to parent  (23,881) 
Total equity: (296)(3,042)5
TOTAL LIABILITIES AND EQUITY: 7482571,306

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

9/30/2015
TTM
12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)		 68026485
Cost of revenue (1)(5) 
Gross profit: 67921485
Operating expenses (4,060)(3,212)(3,547)
Operating loss: (3,380)(3,191)(3,062)
Nonoperating income (expense) 30(198)5
Investment income, nonoperating   4
Other nonoperating income 743
Interest and debt expense (111)(202)(2)
Other undisclosed income from continuing operations before equity method investments, income taxes 1112022
Loss from continuing operations: (3,351)(3,389)(3,058)
Loss before gain (loss) on sale of properties: (3,351)(3,389)(3,058)
Net loss available to common stockholders, diluted: (3,351)(3,389)(3,058)

Comprehensive Income ($ in thousands)
Annual | Quarterly

9/30/2015
TTM
12/31/2014
12/31/2013
12/31/2012
Net loss: (3,351)(3,389)(3,058)
Comprehensive loss, net of tax, attributable to parent: (3,351)(3,389)(3,058)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: